Population screening for colorectal cancer means getting FIT: the past, present, and future of colorectal cancer screening using the fecal immunochemical test for hemoglobin (FIT)

James E Allison, Callum G Fraser, Stephen P Halloran, Graeme P Young, James E Allison, Callum G Fraser, Stephen P Halloran, Graeme P Young

Abstract

Fecal immunochemical tests for hemoglobin (FIT) are changing the manner in which colorectal cancer (CRC) is screened. Although these tests are being performed worldwide, why is this test different from its predecessors? What evidence supports its adoption? How can this evidence best be used? This review addresses these questions and provides an understanding of FIT theory and practices to expedite international efforts to implement the use of FIT in CRC screening.

Keywords: Colorectal cancer; Colorectal cancer screening; Fecal immunochemical test for hemoglobin; Population screening.

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

Figures

Fig. 1
Fig. 1
Cartoon illustrating lateral flow immunochromatographic analysis principle of a fecal immunochemical test for hemoglobin.
Fig. 2
Fig. 2
Variable positivity rates of well-trained, well-supervised, and well-monitored analysts based on their guaiac fecal occult blood test results.
Fig. 3
Fig. 3
Flow chart from invitation to detection with numbers, percentages, and 95% confidence intervals between brackets. Adapted from van Rossum LG, et al. Gastroenterology 2008;135:82-90, with permission from Elsevier. gFOBT, guaiac-based fecal occult blood test; FIT, fecal immunochemical test for hemoglobin.
Fig. 4
Fig. 4
Fecal hemoglobin concentrations in 1,000 consecutive ambulatory patients with increased risk of colorectal neoplasia or symptomatic. Adapted from Levi Z, et al. Ann Intern Med 2007;146:244-255, with permission from American College of Physicians. SD, standard deviation; CI, confidence interval.

References

    1. Potter MB. Strategies and resources to address colorectal cancer screening rates and disparities in the United States and globally. Annu Rev Public Health. 2013;34:413–429.
    1. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19:1893–1907.
    1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
    1. Center MM, Jemal A, Smith RA, Ward E. Worldwide variations in colorectal cancer. CA Cancer J Clin. 2009;59:366–378.
    1. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996;348:1472–1477.
    1. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 1996;348:1467–1471.
    1. Mandel JS, Church TR, Bond JH, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med. 2000;343:1603–1607.
    1. Hoff G, Grotmol T, Skovlund E, Bretthauer M Norwegian Colorectal Cancer Prevention Study Group. Risk of colorectal cancer seven years after flexible sigmoidoscopy screening: randomised controlled trial. BMJ. 2009;338:b1846.
    1. Atkin WS, Edwards R, Kralj-Hans I, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet. 2010;375:1624–1633.
    1. Segnan N, Armaroli P, Bonelli L, et al. Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian Randomized Controlled Trial: SCORE. J Natl Cancer Inst. 2011;103:1310–1322.
    1. Schoen RE, Pinsky PF, Weissfeld JL, et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med. 2012;366:2345–2357.
    1. Shaukat A, Mongin SJ, Geisser MS, et al. Long-term mortality after screening for colorectal cancer. N Engl J Med. 2013;369:1106–1114.
    1. Segnan N, Patnick J, von Karsa L European Commission Directorate General for Health & Consumers; International Agency for Research on Cancer. European guidelines for quality assurance in colorectal cancer screening and diagnosis. 1st ed. Luxembourg: Publications Office of the European Union; 2010.
    1. Halloran SP, Launoy G, Zappa M International Agency for Research on Cancer. European guidelines for quality assurance in colorectal cancer screening and diagnosis: first Edition: faecal occult blood testing. Endoscopy. 2012;44(Suppl 3):SE65–SE87.
    1. Imperiale TF. Noninvasive screening tests for colorectal cancer. Dig Dis. 2012;30(Suppl 2):16–26.
    1. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology. 2008;134:1570–1595.
    1. Ahlquist DA, Skoletsky JE, Boynton KA, et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology. 2000;119:1219–1227.
    1. Osborn NK, Ahlquist DA. Stool screening for colorectal cancer: molecular approaches. Gastroenterology. 2005;128:192–206.
    1. Cole SR, Young GP. Effect of dietary restriction on participation in faecal occult blood test screening for colorectal cancer. Med J Aust. 2001;175:195–198.
    1. Cole SR, Young GP, Esterman A, Cadd B, Morcom J. A randomised trial of the impact of new faecal haemoglobin test technologies on population participation in screening for colorectal cancer. J Med Screen. 2003;10:117–122.
    1. Vart G, Banzi R, Minozzi S. Comparing participation rates between immunochemical and guaiac faecal occult blood tests: a systematic review and meta-analysis. Prev Med. 2012;55:87–92.
    1. Digby J, McDonald PJ, Strachan JA, Libby G, Steele RJ, Fraser CG. Use of a faecal immunochemical test narrows current gaps in uptake for sex, age and deprivation in a bowel cancer screening programme. J Med Screen. 2013;20:80–85.
    1. Fleisher M, Winawer SJ, Zauber AG, Smith C, Schwartz MK. Accuracy of fecal occult blood test interpretation. National Polyp Study Work Group. Ann Intern Med. 1991;114:875–876.
    1. Niv Y. Fecal occult blood test: the importance of proper evaluation. J Clin Gastroenterol. 1990;12:393–395.
    1. Burtonwood C, Butler P, Young M, Halloran S. Monitoring faecal occult blood test positivity in the NHS bowel cancer screening programme. Gut. 2012;61:A334.
    1. Steele RJ, McDonald PJ, Digby J, et al. Clinical outcomes using a faecal immunochemical test for haemoglobin as a first-line test in a national programme constrained by colonoscopy capacity. United Eur Gastroenterol J. 2013;1:198–205.
    1. Stegeman I, de Wijkerslooth TR, Stoop EM, et al. Combining risk factors with faecal immunochemical test outcome for selecting CRC screenees for colonoscopy. Gut. 2014;63:466–471.
    1. Simon JB. Occult blood screening for colorectal carcinoma: a critical review. Gastroenterology. 1985;88:820–837.
    1. Barrows GH, Burton RM, Jarrett DD, Russell GG, Alford MD, Songster CL. Immunochemical detection of human blood in feces. Am J Clin Pathol. 1978;69:342–346.
    1. Songster CL, Barrows GH, Jarrett DD. Immunochemical detection of human fecal occult blood. In: Schottenfeld D, Sherlock P, Winawer SJ, editors. Colorectal cancer, prevention, epidemiology, and screening. Volume 13. New York: Raven Press; 1980. pp. 193–204.
    1. Songster CL, Barrows GH, Jarrett DD. Immunochemical detection of fecal occult blood: the fecal smear punch-disc test: a new non-invasive screening test for colorectal cancer. Cancer. 1980;45(5 Suppl):1099–1102.
    1. Vellacott KD, Baldwin RW, Hardcastle JD. An immunofluorescent test for faecal occult blood. Lancet. 1981;1:18–19.
    1. St John DJ, Young GP, Alexeyeff MA, et al. Evaluation of new occult blood tests for detection of colorectal neoplasia. Gastroenterology. 1993;104:1661–1668.
    1. Williams JA, Hunter R, Smith M, Coles ME, Hubert TW, Thomas DW. Evaluation of an immunological test for occult bleeding from colorectal neoplasia. Aust N Z J Surg. 1982;52:617–621.
    1. Robinson MH, Marks CG, Farrands PA, Thomas WM, Hardcastle JD. Population screening for colorectal cancer: comparison between guaiac and immunological faecal occult blood tests. Br J Surg. 1994;81:448–451.
    1. Rozen P, Knaani J, Papo N. Evaluation and comparison of an immunochemical and a guaiac faecal occult blood screening test for colorectal neoplasia. Eur J Cancer Prev. 1995;4:475–481.
    1. Allison JE, Tekawa IS, Ransom LJ, Adrain AL. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med. 1996;334:155–159.
    1. Petrelli N, Michalek AM, Freedman A, Baroni M, Mink I, Rodriguez-Bigas M. Immunochemical versus guaiac occult blood stool tests: results of a community-based screening program. Surg Oncol. 1994;3:27–36.
    1. Allison JE, Sakoda LC, Levin TR, et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst. 2007;99:1462–1470.
    1. Levi Z, Rozen P, Hazazi R, et al. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med. 2007;146:244–255.
    1. Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology. 2005;129:422–428.
    1. Park DI, Ryu S, Kim YH, et al. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. Am J Gastroenterol. 2010;105:2017–2025.
    1. van Rossum LG, van Rijn AF, Laheij RJ, et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology. 2008;135:82–90.
    1. Allison JE. The imperative of equal funding for studies that evaluate any of the evidence-based, guideline-recommended colorectal cancer screening tests. Clin Gastroenterol Hepatol. 2009;7:1269–1271.
    1. Saito H. Screening for colorectal cancer by immunochemical fecal occult blood testing. Jpn J Cancer Res. 1996;87:1011–1124.
    1. Saito H, Soma Y, Koeda J, et al. Reduction in risk of mortality from colorectal cancer by fecal occult blood screening with immunochemical hemagglutination test. A case-control study. Int J Cancer. 1995;61:465–469.
    1. Shimbo T, Glick HA, Eisenberg JM. Cost-effectiveness analysis of strategies for colorectal cancer screening in Japan. Int J Technol Assess Health Care. 1994;10:359–375.
    1. Cole P, Morrison AS. Basic issues in population screening for cancer. J Natl Cancer Inst. 1980;64:1263–1272.
    1. Levi Z, Hazazi R, Rozen P, Vilkin A, Waked A, Niv Y. A quantitative immunochemical faecal occult blood test is more efficient for detecting significant colorectal neoplasia than a sensitive guaiac test. Aliment Pharmacol Ther. 2006;23:1359–1364.
    1. Young GP, Fraser CG, Halloran SP, Cole S. Guaiac based faecal occult blood testing for colorectal cancer screening: an obsolete strategy? Gut. 2012;61:959–960.
    1. Fletcher RH. Commentary. ACP J Club. 1996;124:74.
    1. Cole SR, Tucker GR, Osborne JM, et al. Shift to earlier stage at diagnosis as a consequence of the National Bowel Cancer Screening Program. Med J Aust. 2013;198:327–330.
    1. Ventura L, Mantellini P, Grazzini G, et al. The impact of immunochemical faecal occult blood testing on colorectal cancer incidence. Dig Liver Dis. 2014;46:82–86.
    1. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, Wilschut J, van Ballegooijen M, Kuntz KM. Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med. 2008;149:659–669.
    1. National Colorectal Cancer Roundtable. Tools & resources: the new FOBT clinician's reference resource [Internet] [place unknown]: National Colorectal Cancer Roundtable; c2002. [cited 2013 Sep 27]. Available from: .
    1. Qaseem A, Denberg TD, Hopkins RH, Jr, et al. Screening for colorectal cancer: a guidance statement from the American College of Physicians. Ann Intern Med. 2012;156:378–386.
    1. Sugerman DT. JAMA Patient Page: options for colorectal cancer screening. JAMA. 2013;310:658.
    1. Quintero E, Castells A, Bujanda L, et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med. 2012;366:697–706.
    1. Allison JE, Fraser CG, Halloran SP, Young GP. Comparing fecal immunochemical tests: improved standardization is needed. Gastroenterology. 2012;142:422–424.
    1. Fraser CG, Allison JE, Young GP, Halloran SP. Newer fecal tests: opportunities for professionals in laboratory medicine. Clin Chem. 2012;58:963–965.
    1. Fraser CG, Halloran SP, Allison JE, Young GP. Making colorectal cancer screening FITTER for purpose with quantitative faecal immunochemical tests for haemoglobin (FIT) Clin Chem Lab Med. 2013;51:2065–2067.
    1. Fraser CG, Allison JE, Halloran SP, Young GP Expert Working Group on Fecal Immunochemical Tests for Hemoglobin, Colorectal Cancer Screening Committee, World Endoscopy Organization. A proposal to standardize reporting units for fecal immunochemical tests for hemoglobin. J Natl Cancer Inst. 2012;104:810–814.
    1. Fraser CG, Allison JE, Young GP, Halloran SP. Quantitation of hemoglobin improves fecal immunochemical tests for noninvasive screening. Clin Gastroenterol Hepatol. 2013;11:839–840.
    1. Tao S, Seiler CM, Ronellenfitsch U, Brenner H. Comparative evaluation of nine faecal immunochemical tests for the detection of colorectal cancer. Acta Oncol. 2013;52:1667–1675.
    1. Grazzini G, Ventura L, Zappa M, et al. Influence of seasonal variations in ambient temperatures on performance of immunochemical faecal occult blood test for colorectal cancer screening: observational study from the Florence district. Gut. 2010;59:1511–1515.
    1. van Roon AH, Hol L, van Vuuren AJ, et al. Are fecal immunochemical test characteristics influenced by sample return time? A population-based colorectal cancer screening trial. Am J Gastroenterol. 2012;107:99–107.
    1. NHS Bowel Cancer Screening Southern Programme Hub (BCSP) Evaluation of quantitative faecal immunochemical tests for haemoglobin [Internet] Surrey: NHS BCSP; 2013. [cited 2014 Feb 3]. Available from: .
    1. Hol L, van Leerdam ME, van Ballegooijen M, et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut. 2010;59:62–68.
    1. Steele RJ, McClements PL, Libby G, et al. Results from the first three rounds of the Scottish demonstration pilot of FOBT screening for colorectal cancer. Gut. 2009;58:530–535.
    1. Denters MJ, Deutekom M, Bossuyt PM, Stroobants AK, Fockens P, Dekker E. Lower risk of advanced neoplasia among patients with a previous negative result from a fecal test for colorectal cancer. Gastroenterology. 2012;142:497–504.
    1. van Roon AH, Goede SL, van Ballegooijen M, et al. Random comparison of repeated faecal immunochemical testing at different intervals for population-based colorectal cancer screening. Gut. 2013;62:409–415.
    1. Crotta S, Segnan N, Paganin S, Dagnes B, Rosset R, Senore C. High rate of advanced adenoma detection in 4 rounds of colorectal cancer screening with the fecal immunochemical test. Clin Gastroenterol Hepatol. 2012;10:633–638.
    1. Potter MB, Ackerson LM, Gomez V, et al. Effectiveness and reach of the FLU-FIT program in an integrated health care system: a multisite randomized trial. Am J Public Health. 2013;103:1128–1133.
    1. Potter MB, Gildengorin G, Wang Y, Wu M, Kroon L. Comparative effectiveness of two pharmacy-based colorectal cancer screening interventions during an annual influenza vaccination campaign. J Am Pharm Assoc (2003) 2010;50:181–187.
    1. Potter MB, Phengrasamy L, Hudes ES, McPhee SJ, Walsh JM. Offering annual fecal occult blood tests at annual flu shot clinics increases colorectal cancer screening rates. Ann Fam Med. 2009;7:17–23.
    1. Potter MB, Somkin CP, Ackerson LM, et al. The FLU-FIT program: an effective colorectal cancer screening program for high volume flu shot clinics. Am J Manag Care. 2011;17:577–583.
    1. Walsh JM, Gildengorin G, Green LW, Jenkins J, Potter MB. The FLU-FOBT Program in community clinics: durable benefits of a randomized controlled trial. Health Educ Res. 2012;27:886–894.
    1. Zajac IT, Whibley AH, Cole SR, et al. Endorsement by the primary care practitioner consistently improves participation in screening for colorectal cancer: a longitudinal analysis. J Med Screen. 2010;17:19–24.
    1. Hewitson P, Ward AM, Heneghan C, Halloran SP, Mant D. Primary care endorsement letter and a patient leaflet to improve participation in colorectal cancer screening: results of a factorial randomised trial. Br J Cancer. 2011;105:475–480.
    1. van Roon AH, Wilschut JA, Hol L, et al. Diagnostic yield improves with collection of 2 samples in fecal immunochemical test screening without affecting attendance. Clin Gastroenterol Hepatol. 2011;9:333–339.
    1. Raginel T, Puvinel J, Ferrand O, et al. A population-based comparison of immunochemical fecal occult blood tests for colorectal cancer screening. Gastroenterology. 2013;144:918–925.
    1. Imperiale TF. Quantitative immunochemical fecal occult blood tests: is it time to go back to the future? Ann Intern Med. 2007;146:309–311.
    1. Fraser CG. A future for faecal haemoglobin measurements in the medical laboratory. Ann Clin Biochem. 2012;49(Pt 6):518–526.
    1. Brenner H, Haug U, Hundt S. Sex differences in performance of fecal occult blood testing. Am J Gastroenterol. 2010;105:2457–2464.
    1. Khalid-de Bakker CA, Jonkers DM, Sanduleanu S, et al. Test performance of immunologic fecal occult blood testing and sigmoidoscopy compared with primary colonoscopy screening for colorectal advanced adenomas. Cancer Prev Res (Phila) 2011;4:1563–1571.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться